- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group for muscle-invasive bladder cancer (MIBC) clinical trial design. Published in the Journal of Clinical Oncology with Dr. Ashish Kamat as lead author, these guidelines aim to advance treatment for urothelial carcinoma. The 25-member panel, including a patien...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on bone health and future directions. They emphasize the importance of bone health, particularly for men with advanced prostate cancer who are at increased risk of bone complications due to age, ADT treatment, and bone metastases. The guidelines recommend assessing the risk of fragility fractu...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines on advanced prostate cancer, focusing on biochemically recurrent prostate cancer without metastasis after local treatment. The guidelines emphasize informing patients about the risk of developing metastatic disease and recommend serial PSA measurements and clinical evaluations. High-risk patients, identified by pathologic grade or...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2023 AUA guidelines for managing lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). They clarify evidence grades: Grade A for high-certainty studies and Grade C for flawed or limited ones. BPH, a proliferation of prostatic tissue, is testosterone-dependent. The duo explains the dynamic and static components contributing to LUT...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the AUA's updated guidelines for managing lower urinary tract symptoms due to BPH, with a focus on medical therapy. They recommend alpha blockers for moderate to severe symptoms, noting all types have similar efficacy in improving IPSS scores. The choice of alpha blocker should be based on patient age, comorbidities, and side effects like ejaculatory dysfunc...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the AUA's updated guidelines for surgical therapy of BPH-related lower urinary tract symptoms. They recommend surgery for patients with complications like renal insufficiency, refractory urinary retention, recurrent UTIs, bladder stones, gross hematuria due to BPH, or when symptoms are unresponsive to other therapies. They note a decrease in TURP surgeries s...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2023 updated AUA guidelines for managing lower urinary tract symptoms (LUTS) attributed to BPH. They focus on evaluating BPH patients, covering initial and follow-up evaluations, pre-operative testing, and treatment failure rates. The initial evaluation includes obtaining a medical history, conducting a physical exam, using the International Prostate Sym...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2023 amended AUA guidelines on advanced prostate cancer. They focus on the epidemiology, early evaluation, and patient counseling. The guidelines, led by Dr. Michael Cookson, form part of a comprehensive six-part series. The discussion highlights the importance of understanding evidence strength, ranging from high-quality randomized trials (Grade A) to st...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the updated AUA guidelines for advanced prostate cancer, focusing on metastatic castration-resistant prostate cancer (mCRPC). The guidelines emphasize the importance of baseline labs, metastatic disease location, and symptoms for prognosis and treatment decisions in mCRPC patients. Statement #25 highlights the significance of various lab markers and metastat...
|
